Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic Patients
The Effect of add-on Tele Medicine Monitoring of Medication Adherence, on the Risk of Re-hospitalisation of Ambulatory Schizophrenic Patients. an Open, Prospective, Randomised Controled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Israel Krieger, Dr. Med
- Phone Number: +97297478665
- Email: israelkr@clalit.org.il
Study Locations
-
-
-
Hod-Hasharon, Israel, 45100
- Recruiting
- Shalvata MHC
-
Contact:
- Israel Krieger, Dr' Med
- Phone Number: +97297478665
- Email: israelkr@clalit.org.il
-
Principal Investigator:
- Israel Krieger, Dr' Med
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- DSM 4 diagnosis of schizophrenia or schizoaffective
- able to give written informed consent
- Have a telephone line
Exclusion Criteria:
- Are not discharged to a place with routine medication monitoring
- Are not discharged under forced ambulatory treatment order
- Are not homeless
- Are not admitted due to drug intoxication or withdrawal.
- Are not admitted due to severe self harm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Experimental: Tele-medicine monitoring
Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
|
|
|
NO_INTERVENTION: No Intervention: Control Rutine out-patient treatment
routine out-patient treatment will be given to the control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to re-hospitalisation
Time Frame: 1 year
|
Time to re-hospitalisation will be compared in the study group and in the control group during the follow-up period of up to one year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of re-hospitalisations
Time Frame: 1 year
|
number of re-hospitalisations will be compared among the study and the control groups during the 1 year follow-up.
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total time in hospital
Time Frame: 1 year
|
Total time in hospital during the 1 year follow-up period will be compared between the study and the control groups.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0004-12-SHA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.